Market Assessment, Asthma Emerging Therapies Nucala mepolizumab US Wave 3 2017 Report

Emerging Therapies: Nucala (US) is a three-wave, syndicated, detailed, expanded analysis that tracks the introduction of Nucala, the first IL-5 inhibitor approved to treat eosinophilic asthma. The series is based on primary research data collected at one month, six months, and one year after Nucala became commercially available. Along with awareness and sources of familiarity, the reports assess U.S. pulmonologists’ and allergists’ trial, adoption, and use of Nucala, including anticipated future trends. The analysis also provides information on product perception, satisfaction, obstacles to use, drivers of prescribing, patient types, displacement of competitors, GlaxoSmithKline’s promotional efforts, and benchmarking against previously launched immune biologics. This module also includes an overview and pipeline analysis of asthma therapies in early- to late-phase clinical development, as well as detailed profiles of, expert insight on, and commercial outlook for select therapies in late-phase development.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Asthma | Emerging Therapies | Nucala (mepolizumab) | US | Wave 3 | 2017

Related Market Assessment Reports

Non-Small-Cell Lung Cancer – Current Treatment – Detailed, Expanded Analysis (US)

Breast Cancer – Unmet Need – Detailed, Expanded Analysis: Advanced Or Metastatic HER2-Positive Breast Cancer (US/EU)

Heart Failure – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Heart Failure – Preserved Ejection Fraction (US)

Male Hypogonadism – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Male Hypogonadism (Low Testosterone) (US)

Heart Failure – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Heart Failure – Reduced Ejection Fraction (US)